JP2020172505A5 - - Google Patents

Download PDF

Info

Publication number
JP2020172505A5
JP2020172505A5 JP2020113725A JP2020113725A JP2020172505A5 JP 2020172505 A5 JP2020172505 A5 JP 2020172505A5 JP 2020113725 A JP2020113725 A JP 2020113725A JP 2020113725 A JP2020113725 A JP 2020113725A JP 2020172505 A5 JP2020172505 A5 JP 2020172505A5
Authority
JP
Japan
Prior art keywords
polypeptide
compound according
amino acid
acid sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020113725A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020172505A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2020172505A publication Critical patent/JP2020172505A/ja
Publication of JP2020172505A5 publication Critical patent/JP2020172505A5/ja
Pending legal-status Critical Current

Links

JP2020113725A 2013-08-28 2020-07-01 ヒト補体c5に結合する安定なポリペプチド Pending JP2020172505A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1350986 2013-08-28
SE1350986-4 2013-08-28

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016537298A Division JP6767865B2 (ja) 2013-08-28 2014-08-28 ヒト補体c5に結合する安定なポリペプチド

Publications (2)

Publication Number Publication Date
JP2020172505A JP2020172505A (ja) 2020-10-22
JP2020172505A5 true JP2020172505A5 (enExample) 2020-12-03

Family

ID=51539238

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016537298A Active JP6767865B2 (ja) 2013-08-28 2014-08-28 ヒト補体c5に結合する安定なポリペプチド
JP2020113725A Pending JP2020172505A (ja) 2013-08-28 2020-07-01 ヒト補体c5に結合する安定なポリペプチド

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016537298A Active JP6767865B2 (ja) 2013-08-28 2014-08-28 ヒト補体c5に結合する安定なポリペプチド

Country Status (29)

Country Link
US (1) US9994626B2 (enExample)
EP (2) EP3038633B1 (enExample)
JP (2) JP6767865B2 (enExample)
KR (1) KR102446636B1 (enExample)
CN (1) CN105658228B (enExample)
AU (1) AU2014314222B2 (enExample)
BR (1) BR112016003142A2 (enExample)
CA (1) CA2926976C (enExample)
CY (1) CY1123732T1 (enExample)
DK (1) DK3038633T3 (enExample)
ES (1) ES2842105T3 (enExample)
HR (1) HRP20210013T1 (enExample)
HU (1) HUE052613T2 (enExample)
IL (1) IL244218A (enExample)
LT (1) LT3038633T (enExample)
MX (1) MX382140B (enExample)
MY (1) MY173804A (enExample)
NZ (1) NZ718153A (enExample)
PH (1) PH12016500371A1 (enExample)
PL (1) PL3038633T3 (enExample)
PT (1) PT3038633T (enExample)
RS (1) RS61347B1 (enExample)
RU (2) RU2733897C2 (enExample)
SA (1) SA516370622B1 (enExample)
SG (1) SG11201602679VA (enExample)
SI (1) SI3038633T1 (enExample)
SM (1) SMT202100006T1 (enExample)
UA (1) UA117933C2 (enExample)
WO (1) WO2015028558A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013126006A1 (en) 2012-02-20 2013-08-29 Swedish Orphan Biovitrum Ab (Publ) Polypeptides binding to human complement c5
PT3038633T (pt) * 2013-08-28 2021-01-14 Ipc Res Llc Polipéptidos estáveis que se ligam ao complemento humano c5
KR102497083B1 (ko) 2013-08-28 2023-02-07 애피바디 에이비 돌연변이된 스캐폴드를 갖는 결합 폴리펩티드
UY37651A (es) * 2017-03-31 2018-10-31 Swedish Orphan Biovitrum Ab Publ Polipéptido de unión al il-1r-i
BR112019028269A2 (pt) 2017-07-11 2020-07-14 Alexion Pharmaceuticals, Inc. polipeptídeos que se ligam ao componente c5 do complemento ou à albumina sérica e suas proteínas de fusão
IL312467A (en) * 2021-11-01 2024-06-01 Ipc Res Llc Administration of c5-binding proteins
WO2024227886A1 (en) 2023-05-02 2024-11-07 Mebrahtu Aman Bispecific binding molecule

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
AU2001296594A1 (en) 2000-10-10 2002-04-22 Tanox, Inc. Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
US7432356B2 (en) 2001-08-17 2008-10-07 Genentech, Inc. Complement pathway inhibitors binding to C5 and C5a without preventing formation of C5b
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
WO2005023866A2 (en) 2003-09-10 2005-03-17 Baxter International Inc. Peptides that inhibit complement activation
SE0400274D0 (sv) * 2004-02-09 2004-02-09 Affibody Ab New polypeptide
GB0518443D0 (en) 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
HUE026496T2 (en) * 2006-03-08 2016-06-28 Archemix Llc Complement-binding aptamers and anti-C5 agents for treating eye diseases
DK2359834T5 (en) 2006-03-15 2017-02-06 Alexion Pharma Inc Treatment of paroxysmal nocturnal hemoglobinuria patients with a complement inhibitor
DE08786222T1 (de) 2007-07-31 2010-11-25 Affibody Ab Neue albuminbindende zusammensetzungen, verfahren und anwendungen
ES2373832T3 (es) 2007-12-19 2012-02-09 Affibody Ab Polipéptido derivado de proteína a y capaz de unirse a pdgf.
US9187535B2 (en) 2007-12-19 2015-11-17 Affibody Ab Polypeptide derived from protein A and able to bind PDGF
EP2072525A1 (en) 2007-12-21 2009-06-24 Affibody AB New polypeptides having affinity for HER2
WO2010015608A1 (en) 2008-08-05 2010-02-11 Novartis Ag Compositions and methods for antibodies targeting complement protein c5
EP2327725A1 (en) 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
CN110437321A (zh) * 2010-07-09 2019-11-12 阿菲博迪公司 多肽
WO2013126006A1 (en) * 2012-02-20 2013-08-29 Swedish Orphan Biovitrum Ab (Publ) Polypeptides binding to human complement c5
JP5980104B2 (ja) 2012-11-22 2016-08-31 三菱電機株式会社 液晶表示装置の製造方法および液晶表示装置の製造システム
US9957330B2 (en) 2012-12-19 2018-05-01 Affibody Ab Polypeptides
PT3038633T (pt) * 2013-08-28 2021-01-14 Ipc Res Llc Polipéptidos estáveis que se ligam ao complemento humano c5
KR102497083B1 (ko) 2013-08-28 2023-02-07 애피바디 에이비 돌연변이된 스캐폴드를 갖는 결합 폴리펩티드

Similar Documents

Publication Publication Date Title
JP2020172505A5 (enExample)
EP2349310B1 (en) Polypeptide for treating or preventing adhesions
JP2010534486A5 (enExample)
RU2014137303A (ru) Полипептиды, связывающиеся с компонентом с5 системы комплемента человека
JP2018537087A5 (enExample)
JP2006149365A5 (enExample)
JP2015508652A5 (enExample)
JP2017521074A5 (enExample)
CN103459419B (zh) 具有抗炎活性的基于人乳铁蛋白的肽
JP2018537089A5 (enExample)
RU2016111115A (ru) Стабильные полипептиды, связывающиеся с с5 комплемента человека
JP2017527558A5 (enExample)
US9060977B2 (en) Heparin binding epidermal growth factor (HB-EGF) for use in methods of treating and preventing intestinal injury related to hemorrhagic shock and resuscitation
JP2020518249A5 (enExample)
WO2021198395A1 (en) Surfactant protein d for use in treating coronavirus infections
JP2004537284A5 (enExample)
JP6532141B2 (ja) 肝細胞増殖因子及びストローマ細胞由来因子1αを用いた末梢動脈疾患の予防または治療用組成物
JP2015525237A5 (enExample)
JP2009507474A5 (enExample)
JP2008502323A5 (enExample)
JP2024133479A5 (enExample)
JP2019525764A5 (enExample)
JP2002539829A5 (enExample)
JP2001072607A (ja) 新規血管内皮機能改善法
JP2013514811A5 (enExample)